UBS’s Ocular Therapeutix OCUL Stock Holding History

UBS’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$19K	Buy	+1,272	New	+$18.8K	﹤0.01%	8080

Other funds holding OCUL

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS's OCUL Position: Q3 2014 in Review

UBS opened a new position in Ocular Therapeutix (OCUL) in Q3 2014: 1,272 shares worth $19K. The stake represents ﹤0.01% of the portfolio and ranks #8080 among its holdings.

34 funds tracked by Wall St. Rank hold OCUL as of Q3 2014.

UBS held 1,272 shares of Ocular Therapeutix worth $19K as of Q3 2014.
Ocular Therapeutix was a new UBS position in Q3 2014.
Ocular Therapeutix made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8080 holding.
34 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.